<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115802">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01651468</url>
  </required_header>
  <id_info>
    <org_study_id>HEMOFIX- HMO-CTIL</org_study_id>
    <nct_id>NCT01651468</nct_id>
  </id_info>
  <brief_title>The Effect of the Nutraceutical &quot;Hemofix&quot; on the Coagulation System</brief_title>
  <official_title>Phase 1 Study of the Nutraceutical &quot;Hemofix&quot; Safety and Effect on the Coagulation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HEMOFIX</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yocheved Grossman</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Idan Grossman</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to
      assist in wound healing and bleeding arrest. It contains herbs such as Red Clover,
      Liquorice, Raspberry, Ginger and more. The present study will evaluate the formula on the
      coagulation system.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>bleeding and blood test results</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Von Willebrand Disease</condition>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>HEMOFIX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 grams a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HEMOFIX</intervention_name>
    <description>unique complex herbal mixture</description>
    <arm_group_label>HEMOFIX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers and volunteers with a  mild bleeding disorder

        Exclusion Criteria:

          -  people with thrombophilic  and cardiovascular complications,

          -  people who  are treated with anti-coagulants,

          -  women taking birth control pills

          -  people with a history hypercoagulability
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Varon, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>HMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>David Varon, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 28, 2012</lastchanged_date>
  <firstreceived_date>July 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>David Varon</investigator_full_name>
    <investigator_title>Director of coagulation unit</investigator_title>
  </responsible_party>
  <keyword>mild bleeding disorder</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
